<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121273</url>
  </required_header>
  <id_info>
    <org_study_id>v1.0 20180620</org_study_id>
    <nct_id>NCT04121273</nct_id>
  </id_info>
  <brief_title>GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC</brief_title>
  <official_title>Clinical Study of GPC3-targeted Chimeric Antigen Receptor T Cells fo Treating Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hepatocellular carcinoma (a type of primary liver cancers) are enrolls in this
      study. The cancer has progressed after standard treatment, or the patient cannot receive
      regular treatment.

      Investigator made a gene called chimeric antigen receptor derived from an antibody that
      recognizes Glypican 3, a protein detected in in a large proportion of hepatocellular
      carcinoma. The gene will introduce into T cell from patient's blood to make them recognize
      and kill cancer cells.

      The aim of this study is to evaluate the efficacy, tolerance and safety of chimeric antigen
      receptor-modified T (CAR-T) cell targeting Glypican 3 for advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient with dose limiting toxicity</measure>
    <time_frame>2 months</time_frame>
    <description>After each dose of T cell infusion, the adverse effects related to T cell therapy such as fever and jaundice are observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological evaluation of tumor size after CAR- T immunotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the therapeutic effect of CAR-T immunotherapy radiological observation of the tumor size after infusion of CAR-T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral tumor marker</measure>
    <time_frame>3 months</time_frame>
    <description>After CAR-T cell infusion, alpha fetoprotein (AFP) will be tested regularly in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Peripheral CAR-T cell</measure>
    <time_frame>3 months</time_frame>
    <description>The number and proliferation in vivo are tested with Flow Cytometry regularly.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cell immunotherapy</intervention_name>
    <description>Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:
Dose 1: 1x10^7/m2
Dose 2: 3x10^7/m2
Dose 3: 1x10^8/m2
The cell numbers are calculated according to CAR-positive T cells.</description>
    <arm_group_label>CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. GPC3 positive HCC, tumor size &gt;= 5 cm, cannot receive standard treatment, Expected
             survival time&gt;=3 months.

          2. Routine blood test: white blood cell count（WBC)&gt;= 2.5×10^9/L, hemoglobin (Hb)&gt;= 9.0
             g/dL, blood platelet &gt;= 60×10^9/L, Lymphocyte percentage&gt;=15%.

          3. Blood biochemical parameters: ALB &gt;= 30 g/L, ALT &lt;= 5 times of the normal value, AST
             &lt;= 5 times of the normal value, serum lipase&lt;=1.5 times of the normal value, serum
             amylase&lt;=1.5 times of the normal value， total bilirubin &lt;= 2.5 times of the normal
             value.

          4. Prothrombin time INR &lt; 1.7.

          5. Ejection fraction (EF) &gt;= 55%, oxygen saturation (SO2) &gt; 90%.

          6. No allergic reaction to contrast material.

          7. Karnofsky score &gt;= 60%.

          8. Child-puge score &lt;7.

          9. Peripheral venous access.

         10. Voluntarily signed informed consent.

        Exclusion Criteria:

          1. Pregnancy or lactation.

          2. Systemic steroid treatment ( &gt;prednisone equivalent/kg/day).

          3. Patients with previous history of cell immunotherapy or antibody therapy.

          4. Patients received radiotherapy/chemotherapy in the past 4 weeks.

          5. Patients are participating in other clinical trials.

          6. Patients with uncontrolled symptoms including infection, heart failure, arrhythmia.

          7. Patients with acute allergic reaction.

          8. History of liver transplantation.

          9. Patients with anticoagulant treatment.

         10. Patients with hepatic encephalopathy.

         11. Eligible for hepatectomy, liver transplantation or other standard treatment.

         12. Unstable gastrointestinal and respiratory bleeding.

         13. Active viral, fungal or bacterial infections.

         14. Heart failure classification (NYHA): II-IV.

         15. Patients are unable or unwilling to comply with the requirements of the study
             protocol.

         16. Patients do not meet the criteria above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Decai Yu, MD</last_name>
    <phone>8613701585023</phone>
    <email>yudecai@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenfang Tian, PhD</last_name>
    <phone>8613675104348</phone>
    <email>tiancpu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenfang Tian, PhD</last_name>
      <phone>8613675104348</phone>
      <email>tiancpu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Beicheng Sun</investigator_full_name>
    <investigator_title>Director of Hepatobiliary Surgery</investigator_title>
  </responsible_party>
  <keyword>chimeric antigen receptor T cell (CAR- T)</keyword>
  <keyword>glypican-3 (GPC3)</keyword>
  <keyword>hepatocellular carcinoma (HCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

